Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.61 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.52 |
| ▸ | PTPRC | P08575 | 3/20 | 0.49 |
| ▸ | CDC25B | P30305 | 2/20 | 0.49 |
| ▸ | PTPRF | P10586 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.47 |
| ▸ | CDC25A | P30304 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | S100A4 | P26447 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712387 | 0.88 | TTR (0.61) | TTRPDK2PTPRCCDC25BPTPRF | |
| SCHEMBL9685987 | 0.83 | TTR (0.67) | TTRPTPRCMAPTMITFTSHR | |
| SCHEMBL9423198 | 0.82 | TTR (0.55) | TTRPTPRCMAPTMITFFGFR1 | |
| SCHEMBL9685937 | 0.82 | MAPT (0.46) | TTRPTPRCCDC25BPTPRFPTPN1 | |
| SCHEMBL4919949 | 0.79 | FGFR1 (0.51) | TTRPTPRCCDC25BPTPRFPTPN1 | |
| SCHEMBL23199032 | 0.79 | BCL2 (0.57) | TTRMAPTMITFTSHR | |
| SCHEMBL26120300 | 0.78 | S100A4 (0.62) | TTRPDK2PTPRCCDC25BPTPRF | |
| SCHEMBL4921071 | 0.78 | TTR (0.61) | TTRPTPRCCDC25BPTPRFPTPN1 | |
| SCHEMBL10072581 | 0.76 | PDK2 (0.46) | TTRPDK2PPARAMAPTTSHR | |
| SCHEMBL10832764 | 0.76 | CA1 (0.58) | PDK2PPARAMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | TTR 55/4885PDK2 3616/4885PTPRC 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.